摘要
Objective To evaluate the efficacy and safety of bortezomib-based chemotherapy for 80 patients with multiple myeloma(MM).Methods A total of 80 cases with a median age of 57(range:25-78)years were enrolled in the study.Bortezomib-based regimens included VD(bortezomib and dexamethasone)and PAD(bortezomib,doxorubicin and dexamethasone).16 of the 80
